We previously reported the successful RCT of our smartphone app-based lifestyle intervention in overweight or obese subjects (ClinicalTrials.gov NCT02742662). Our intervention met the prespecified primary outcome of clinically meaningful, statistically significant weight loss at 6 months over standard of care in wait-listed controls (ADA 2018). Here we report effects of the intervention on glycemia and risk of diabetes as assessed by A1c, a prespecified secondary endpoint. The app downloads daily weights from smartscales and physical activity from 3-axis accelerometers. The technology allows peer social networking and remote coaching. Subjects chose diets from a selection of low glycemic index, low fat, low carb or Mediterranean. We performed comparisons using the t test. Intervention group (I) N=13, no dropouts, 84.62% F, age 40.2 ± 3.73 y (means ± SE), initial weight 94.2 ± 3.41 kg, BMI 34.5 ± 1.25 kg/m2. Wait-listed Control group (C) n=15, 86.67% F, age 45.9 ± 3.29 y, initial weight 92.3 ± 4.37 kg, BMI 34.4 ± 1.48 kg/m2. N=14 began the study and received in-person weight management visits at 0, 3, and 6 months. N=10 completed the 6-12 month phase during which they received the app-based lifestyle intervention. The intervention significantly improved A1c at 6 months -0.251 ± 0.0894 (95% CI -0.4419 to -0.0609) p=0.013 (I over C, per protocol analysis). At 6 months (I) change in A1c (n=9) -0.189 ± 0.0389 (95% CI -0.2786 to -0.0992) p= 0.0013, (C) change in A1c (n=8) +0.0625 ± 0.0844 (95% CI -0.1370 to 0.2620) p=0.48. After receiving the intervention from 6-12 months (C) group (n=10) improved A1c by -0.26 ± 0.0718 (95% -0.4224 to -0.0976) p=0.0056. All (C) subjects with prediabetes (n=4 of 10) who received the intervention resolved prediabetes at 12 months. Thus, the intervention produced clinically and statistically significant improvements in A1c. Our smartphone app-based lifestyle intervention may be a useful tool to treat prediabetes and prevent diabetes.


C. Vaz: None. N. Carnes: None. H. Zhao: None. K. Williams: Advisory Panel; Self; Gemphire Therapeutics Inc. Stock/Shareholder; Self; Gemphire Therapeutics Inc., Hygieia.


Temple University; Obesity Treatment Foundation

Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at http://www.diabetesjournals.org/content/license.